Skip to content

Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer

Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00310479
Enrollment
16
Registered
2006-04-04
Start date
2006-06-30
Completion date
2008-03-31
Last updated
2016-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Magnetic Resonance Imaging, prostate cancer imaging, 3T MRS, functional imaging

Brief summary

We seek to develop an advanced imaging approach to identifying and localizing prostate cancer. We believe that high field MRI (magnetic resonance imaging) has the potential to do this and we will endeavor to prove this by having patients with prostate cancer pre-operatively undergo a technique called magnetic resonance spectroscopy. After surgery, the microscopic locations of cancer will be compared with the pre-operative images to assess how well the imaging technique succeeds.

Detailed description

The proposed research is enormously relevant to the clinical understanding of early prostate cancer. We propose to test to see whether characteristic patterns of invivo 3T MRSI associated metabolites can be identified in correlation with clinically active tumor reserved on histopathologic analysis of resected specimens. We also plan to demonstrate that 3T MR spectra of prostate cancer will allow for more detailed metabolic assessment with higher sensitivity, specificity and accuracy and publish results established from MR spectra using 1.5T MR units. Functional imaging (eg. molecular imaging such as this) is felt to be the clinical wave of the future for cancer imaging, and if successful, will assume a very major role in the detection, assessment, treatment planning and delivery of drugs, radiation, heat and novel therapeutics in the fight against prostate cancer.

Interventions

DEVICEMagnetic Resonance Spectroscopy (3Tesla)

Sponsors

Cross Cancer Institute
CollaboratorOTHER
AHS Cancer Control Alberta
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically verified prostate cancer * Patient has opted for surgery * Low risk prostate cancer PSA \<1 0, Gleason \< 7, Stage \< T2b * No contraindication to MR scanning * No prior history of malignancy * Fit for surgery

Exclusion criteria

* Nonbiopsied lesion * Intermediate or high risk prostate cancer * Unfit for surgery * Contraindication to MR scanning (i.e. pacemaker, aneurysm clips, claustrophobia)

Design outcomes

Primary

MeasureTime frame
characteristic metabolic pattern of prostate cancer at 3Tesla

Secondary

MeasureTime frame
specificity, accuracy, NPV
PPV of MRS in the detection of prostate cancer

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026